Featured Publications
Cell Death in the Lung: The Apoptosis–Necroptosis Axis
Sauler M, Bazan IS, Lee PJ. Cell Death in the Lung: The Apoptosis–Necroptosis Axis. Annual Review Of Physiology 2018, 81: 1-28. PMID: 30485762, PMCID: PMC6598441, DOI: 10.1146/annurev-physiol-020518-114320.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsRegulated cell deathCell deathAutophagic cell deathCell death mechanismsSuperfluous cellsAcute respiratory distress syndromeChronic obstructive pulmonary diseasePulmonary arterial hypertensionIdiopathic pulmonary fibrosisObstructive pulmonary diseaseRespiratory distress syndromeDeath mechanismsCellular mechanismsArterial hypertensionDistress syndromePulmonary diseasePulmonary fibrosisPulmonary disordersMajor mechanismDeathNew modalityPathogenesisNecroptosisMechanismApoptosis
2024
Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis.
Trujillo G, Regueiro-Ren A, Liu C, Hu B, Sun Y, Ahangari F, Fiorini V, Ishikawa G, Al Jumaily K, Khoury J, McGovern J, Lee C, Peng X, Pivarnik T, Sun H, Walia A, Woo S, Yu S, Antin-Ozerkis D, Sauler M, Kaminski N, Herzog E, Ryu C. Toll-like Receptor 9 Inhibition Mitigates Fibroproliferative Responses in Translational Models of Pulmonary Fibrosis. American Journal Of Respiratory And Critical Care Medicine 2024 PMID: 39189851, DOI: 10.1164/rccm.202401-0065oc.Peer-Reviewed Original ResearchToll-like receptor 9Model of pulmonary fibrosisIdiopathic pulmonary fibrosisPulmonary fibrosisFibroproliferative responseLung diseaseIdiopathic pulmonary fibrosis cohortsExpression of toll-like receptor 9Toll-like receptor 9 activationTransplant-free survivalExpression of MCP-1Cohort of patientsSlow clinical progressionFibrotic lung diseaseAccelerated disease courseFatal lung diseaseIP-10Pharmacodynamic endpointsPreclinical modelsDisease courseClinical progressionPlasma mtDNAMCP-1Receptor 9Mouse modelAlveolar Type 2 Cells With Impaired Proteostasis Signal to Monocyte-derived Macrophages Via a MIF/DDT-CD74 Signaling Network to Promotes Pulmonary Fibrosis in IPF
Kim S, Nouws J, Cooley J, Ahangari F, Leng L, Elias J, Kaminski N, Lee P, Redente E, Kang M, Sun H, Herzog E, Bucala R, Prasse A, Sauler M. Alveolar Type 2 Cells With Impaired Proteostasis Signal to Monocyte-derived Macrophages Via a MIF/DDT-CD74 Signaling Network to Promotes Pulmonary Fibrosis in IPF. 2024, a3001-a3001. DOI: 10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a3001.Peer-Reviewed Original Research
2023
A statistical framework to identify cell types whose genetically regulated proportions are associated with complex diseases
Liu W, Deng W, Chen M, Dong Z, Zhu B, Yu Z, Tang D, Sauler M, Lin C, Wain L, Cho M, Kaminski N, Zhao H. A statistical framework to identify cell types whose genetically regulated proportions are associated with complex diseases. PLOS Genetics 2023, 19: e1010825. PMID: 37523391, PMCID: PMC10414598, DOI: 10.1371/journal.pgen.1010825.Peer-Reviewed Original ResearchConceptsCell typesDisease-associated tissuesWide association studyComplex diseasesCell type proportionsDisease-relevant tissuesReal GWAS dataFunctional genesTranscriptomic dataGWAS dataGenetic dataAssociation studiesNovel statistical frameworkChronic obstructive pulmonary diseaseStatistical frameworkObstructive pulmonary diseaseIdiopathic pulmonary fibrosisBreast cancer riskType proportionsBlood CD8Pulmonary diseasePulmonary fibrosisPredictive biomarkersLung tissueBreast cancerVISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis.
Kim S, Adams T, Hu Q, Shin H, Chae G, Lee S, Sharma L, Kwon H, Lee F, Park H, Huh W, Manning E, Kaminski N, Sauler M, Chen L, Song J, Kim T, Kang M. VISTA (PD-1H) Is a Crucial Immune Regulator to Limit Pulmonary Fibrosis. American Journal Of Respiratory Cell And Molecular Biology 2023, 69: 22-33. PMID: 36450109, PMCID: PMC10324045, DOI: 10.1165/rcmb.2022-0219oc.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisPulmonary fibrosisImmune regulatorsTherapeutic potentialHuman idiopathic pulmonary fibrosisCrucial immune regulatorsNovel immune regulatorPulmonary fibrosis micePulmonary fibrosis modelNovel therapeutic targetRole of VISTAWild-type littermatesMonocyte-derived macrophagesT lymphocyte lineageVISTA expressionIPF treatmentAntibody treatmentImmune landscapeFibrotic mediatorsLung fibrosisFibrosis miceInflammatory responseFibrosis modelMyeloid populationsTherapeutic target
2022
A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis
Chioccioli M, Roy S, Newell R, Pestano L, Dickinson B, Rigby K, Herazo-Maya J, Jenkins G, Ian S, Saini G, Johnson SR, Braybrooke R, Yu G, Sauler M, Ahangari F, Ding S, DeIuliis J, Aurelien N, Montgomery RL, Kaminski N. A lung targeted miR-29 mimic as a therapy for pulmonary fibrosis. EBioMedicine 2022, 85: 104304. PMID: 36265417, PMCID: PMC9587275, DOI: 10.1016/j.ebiom.2022.104304.Peer-Reviewed Original ResearchConceptsIdiopathic pulmonary fibrosisNon-human primatesPulmonary fibrosisAnimal modelsPro-fibrotic genesAnti-fibrotic efficacyMiR-29 mimicsHuman peripheral bloodMiR-29b levelsHuman lung fibroblastsIPF patientsIPF diagnosisPeripheral bloodReduced fibrosisAdverse findingsPotential therapyLung slicesTGF-β1Relevant dosesLung fibroblastsNIH-NHLBIFibrosisTherapyCollagen productionProfibrotic gene program
2021
Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing
Kato K, Shin YJ, Palumbo S, Papageorgiou I, Hahn S, Irish JD, Rounseville SP, Krafty RT, Wollin L, Sauler M, Hecker L. Leveraging ageing models of pulmonary fibrosis: the efficacy of nintedanib in ageing. European Respiratory Journal 2021, 58: 2100759. PMID: 34531276, PMCID: PMC8613836, DOI: 10.1183/13993003.00759-2021.Peer-Reviewed Original ResearchConceptsEfficacy of nintedanibIdiopathic pulmonary fibrosisAged miceLung fibrosisPulmonary fibrosisElderly patientsLung functionPre-clinical efficacy studiesAged animal modelsIPF clinical trialsVital capacity declineAverage patient ageVehicle-treated miceVehicle-treated groupEffect of nintedanibSeverity of fibrosisDevelopment of fibrosisTotal lung collagenSimilar extentNintedanib treatmentLung injuryPatient ageIPF diagnosisClinical efficacyFibrosis severity
2020
Non-coding RNAs as Regulators of Cellular Senescence in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease
Omote N, Sauler M. Non-coding RNAs as Regulators of Cellular Senescence in Idiopathic Pulmonary Fibrosis and Chronic Obstructive Pulmonary Disease. Frontiers In Medicine 2020, 7: 603047. PMID: 33425948, PMCID: PMC7785852, DOI: 10.3389/fmed.2020.603047.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsNon-coding RNAsCellular stress responseNon-coding RNACellular senescenceCell fateChronic obstructive pulmonary diseaseStress responseAlternative cell fatesIdiopathic pulmonary fibrosisLong non-coding RNAsObstructive pulmonary diseaseCellular stressorsCellular stressKey regulatorSenescencePulmonary diseaseDNA damagePulmonary fibrosisMitochondrial dysfunctionRNACellular mechanismsChronic lung diseasePotential therapeutic roleRegulatorOxidative stress
2015
Role of macrophage migration inhibitory factor in age-related lung disease
Sauler M, Bucala R, Lee PJ. Role of macrophage migration inhibitory factor in age-related lung disease. American Journal Of Physiology - Lung Cellular And Molecular Physiology 2015, 309: l1-l10. PMID: 25957294, PMCID: PMC4491511, DOI: 10.1152/ajplung.00339.2014.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMacrophage migration inhibitory factorAge-related lung diseaseMigration inhibitory factorLung diseaseInhibitory factorChronic obstructive lung diseaseChronic lung diseaseObstructive lung diseaseCommon respiratory disorderPulmonary fibrosisClinical manifestationsProinflammatory cytokinesLung cancerRespiratory disordersImmune systemVariant allelesDiseaseHost factorsSuch diseasesPotent upstream regulatorUpstream regulatorPneumoniaFibrosisBody of literatureCytokines